@article{54ea04add5e242de8548bc3ea8754858,
title = "Editorial: Precision psychiatry from a pharmacogenetics perspective",
keywords = "genetics, personalized medicine, pharmacogenetics, pharmacogenomic (PGx) research, precision medicine, psychiatry",
author = "Brown, {Lisa C.} and Allen, {Josiah D.} and Eyre, {Harris A.} and Baune, {Bernhard T.} and Aitchison, {Katherine J.} and Bousman, {Chad A.}",
note = "Funding Information: LB was previously employed by and/or owned stock in Myriad Genetics and Tempus Labs. LB has served as a consultant for the following organizations: IQ Genetix, InnovativeGX, Tempus Labs, Headlamp Health. She is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Pharmacogene Variation Consortium (PharmVar), the Pharmacogenetics Research Network (PGRN), and the International Society of Psychiatric Genetics (ISPG). JA has served as a consultant for the following organizations: Mobility Health, Nurture Genomics, Precision Genetics, Tempus Labs. HE was previously employed by CNSdose Pty Ltd. BB received speaker honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen, LivaNova, Lundbeck, Novartis, Otsuka, Pfizer, Servier, Wyeth, Biogen, Angelini, and Sumitomo Pharma. KA has received a research grant from Janssen Inc., Canada (fellowship for a trainee), and in-kind research support from Thermo Fisher Scientific, Luminex, Pacific Biosciences of California, and Agena Bioscience. She is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Pharmacogene Variation Consortium (PharmVar), and the Genetic Testing Committee of the International Society of Psychiatric Genetics (ISPG). CB is founder and CEO of Sequence2Script Inc. LB was employed by Great Scott! Consulting. JA was employed by Medigenics Consulting. ",
year = "2023",
doi = "10.3389/fpsyt.2023.1159000",
language = "English (US)",
volume = "14",
pages = "1159000",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Media S. A.",
}